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ABSTRACTS
Gregory L. Moneta, MD, Section Editor
Are Patients with Thrombophilia and Previous Venous Thromboem-
bolism at Higher Risk for Arterial Thrombosis?
Linnemann B, Schindewolf M, Zgouras D, et al. Thrombosis Research
2008;121:743-750.
Conclusion: Inherited thrombophilias do not substantially increase
the risk of arterial thrombosis.
Summary: Inherited thrombophilias are well recognized to increase
the risk of venous thromboembolism. The relationship between inherited
thrombophilias and arterial thrombosis is more controversial. A large meta-
analysis found a weak relationship between common genetic thrombophilias
and arterial thrombotic events with calculated odds ratios of 1.2 for Factor V
Leiden mutation and 1.3 for prothrombin gene mutation. Neither of these
calculations was adjusted for clinical concomitant cardiovascular risk factors.
The authors sought to use data from 1,081 consecutive patients (649
females and 432 males, 16-93 years of age) who were registered in a venous
thromboembolism registry in Germany. Patients were screened for Factor V
Leiden and prothrombin G20210A mutation, anticardiolipin antibodies,
and activities of factor VIII, protein C, protein S, and antithrombin.
In this study cohort, 40 patients or 3.7% had a prior myocardial
infarction and 3.8% (n41) had suffered a stroke. Other arterial thrombotic
events were infrequent. Factor VIII levels were more often elevated in
myocardial infarction (MI) patients than in controls (44.4% v. 25.9%,
p0.044) but this relationship did not hold after adjusting for traditional
cardiovascular risk factors. There was also an observed higher rate of lupus
anticoagulant inmyocardial infarction patients with an adjusted odds ratio of
3.3 (95% CI 0.84-12.8, p0.090). No differences in other tested thrombo-
philias approached significance in patients with MI or stroke relative to
control patients without MI or stroke.
Comment: Vascular surgeons sometimes see patients they feel are
“hypercoagulable”. I am sure a very few of them actually are but most are
probably just the victim of a technically imperfect procedure. Nevertheless,
testing for hypercoagulable states is common in vascular surgical patients.
This paper tells us native artery events induced by recognized thrombo-
philias are rare. It does not tell us if thrombophilias contribute to failed
arterial reconstructions. My belief, however, is genetically based throm-
bophilias are a very infrequent cause of a failed arterial reconstruction.
Just as “abnormal anatomy” is often the indicator of a confused surgeon,
so is it also that post-operative “hypercoagulable states” are more likely
the result of surgical imperfections than genetic abnormalities of the
coagulation system.
Cognitive Changes in Retirement among Senior Surgeons (CCRASS):
Results from the CCRASS Study
Bieliauskas LA, Langenecker S, Graver C, et al. J Am College Surgery
2008;207:69-79.
Conclusion: Surgeons demonstrate age related declines in attention,
reaction time, visual learning andmemory but are above normative values for
age. Self perceived cognitive changes play a role in surgeon’s decisions to
retire but are not related to objective measures of cognitive change.
Summary: After 60 years of age, most surgeons reduce their operative
work load considerably but 17% continue to operate even after after 70 years
of age (Ann Surg 1994; 220:382-390). Cognitive efficacy decreases mark-
edly after 75 years of age and while, with age there is an accumulated wisdom
and verbal knowledge, there is still an overall decline in cognitive processing
efficiency. In this study, the author studied the logic behind surgeons’
decisions to retire with specific emphasis on the role of perceived or con-
firmed cognitive decline in the decision to retire.
The authors administered three subtests from the Cambridge Neuro-
psychological Test Automated Battery to 359 surgeons at the annual meet-
ing of the American College of Surgeons over a six year period. These tests
measured sustained attention, reaction time, visual learning and memory.
The surgeons were also administered a survey to assess subjective cognitive
changes and the status of their surgical practice and retirement decisions.
The study demonstrated expected age related cognitive declines in all
measures. Measured reaction time, however, was notably better than among
age appropriate controls. There was an age related decrease in volume of
patients (p0.001), decrease in complexity of cases (p0.0001), and a
decrease in mastery of new technologic developments (p0.03). Surgeons
who reported that they had not consumed any alcohol in the 24 hours prior
to testing had slower reaction times than those who had consumed more
than two (p0.001) andmore than six drinks (p0.003) in the same period.
There was a marked relationship between surgeon’s self-reported cognitive
change and actual and anticipated retirement status. However, there was no
relationship between subjective cognitive change and objective measure-
ments of cognitive decline.
Comment: A surgeon’s decision to retire may be based on reaching a
specific age, or actual or perceived decline in cognitive or technical ability. In
this study, only 18% of surgeons based their decision to retire on age alone.
A self-perceived decline in cognitive abilities was, however, strongly associ-
ated with retirement status but objective measurements of cognitive decline
did not correlate with self perceptions of cognitive decline. Surgeons in
many cases may be choosing to retire pre-maturely.
Contaminated Heparin Associated with Adverse Clinic Events and
Activation of the Contact System
Kishimoto TK, Viswanathan K, Ganguly T, et al. N Engl J Med 2008;358:
2457-67.
Conclusion: Recent deaths associated with contaminated heparin ap-
pear to be mediated by activation of the contact system by over-sulfated
chondroitin sulfate (OSCS).
Summary: Beginning in November 2007 some patients undergoing
dialysis were developing symptoms of hypotension, facial swelling, tachycar-
dia, uticaria, and nausea. This was initially linked to heparin sodium for
injection (1000 units per ml, in 10 ml and 30 ml multi-dose vials) manufac-
tured by Baxter Healthcare. Initial recall of heparin sodium occurred on
January 17, 2008 and by April 13, 2008 there were 81 reports of death with
at least one sign or symptom of allergic reaction in patients receiving heparin
since January 1, 2007. On March 6, 2008 a similar cluster of events was
announced in Germany associated with heparin provided by a different
manufacturer. Subsequently, upon recommendations from the FDA, hepa-
rin was screened for contamination and widespread contamination of the
heparin supply in at least 12 countries was discovered. This contaminate was
identified as an unusual over-sulfated form of chondroitin sulfate (OSCS).
No other contaminates were observed. In this paper, the author sought to
establish a biologic link between OSCS and allergic type clinical manifesta-
tions occurring in patients receiving heparin.
The authors procured heparin from the FDA. This consisted of lots of
heparin associated with the clinical events reported as well as control lots.
The suspected and control lots were then screened in a blinded fashion for
presence of OSCS and for any biologic activity that could potentially link
OSCS to the observed clinical events. Activation of the complement cascade
and the contact system was investigated with in vitro assays. A swine model
was also used to test the ability of OSCS to duplicate the clinical manifesta-
tions associated with the adverse allergic type reactions to the contaminated
heparin lots.
In the contaminated lots of heparin, OSCS was found to directly
activate the kinin-kallikrein pathway. Activation of this pathway can lead to
generation of bradykinin, a potent vasoactive mediator. Generation of C3a
and C5a was also induced by OSCS. These are potent anaphylatoxins
derived from complement proteins. Plasma samples screened from various
species indicated that swine and humans were sensitive to the effects of
OSCS in a similar fashion. The authors then determined that OSCS con-
taining heparin and synthetically derived OSCS both induced hypotension
associated with kallikrein activity when administered intravenously in the pig
model.
Comment: The author’s results provide scientific rationale for a bio-
logic link between OSCS in contaminated lots of heparin and observed
clinical adverse events. This is elegant work and essentially a modern appli-
cation of Koch’s postulate. In the future, the heparin supply will need to be
screened for OSCS and other highly sulfated polysachride contaminates that
may activate the contact system and lead to serious adverse events.
Cost-Effectiveness of Endarterectomy in Patients with Asymptomatic
Carotid Artery Stenosis
Henriksson M, Lundgren F, Carlsson P. Brit J Surg 2008;95:715-720.
Conclusion: In patients with asymptomatic carotid stenosis, carotid
endarterectomy, in addition to best medical management, is cost effective in
men age 73 years or less. It is unlikely to be cost effective in older men or in
women.
Summary: Major randomized trials of carotid endarterectomy (CEA)
in addition to best medical management compared to best medical manage-
ment alone have indicated CEA is effective in reducing strokes in the patient
populations studied. The cost effectiveness of such a strategy in asymptom-
atic patients has not been well studied. In this study, the authors investigated
the cost effectiveness of CEA for asymptomatic patients in comparison to a
769
strategy of best medical management alone. The authors developed a
Markov transition model to model disease progression and use of resources
for both CEA combined with best medical management or the strategy of
best medical management alone. The model was based on data from the
randomized asymptomatic carotid surgery trial (ACST), a National Swedish
Vascular Database, and expected costs and health outcomes in terms of
quality adjusted life years (QALYs). Cost effectiveness was established for a
Swedish setting from the Swedish societal perspective.
(Base-case analysis showed incremental cost per QALY of CEA for a
65- and 75- year old man/woman was 34,557 Euros and 311,133 Euros
and 58,930 Euros and 779,776 Euros respectively. A sensitivity analysis
indicated that a duration of treatment effect of five years was important for
the cost effectiveness results. An additional five-year duration of treatment
effect (10 years total) indicated that the cost in Euros per QALY gained from
CEA was 13,748 for men age 65 years and 31,384 for men age 75 years. For
an additional 10 year duration of treatment effect (15 years total) the cost
per QALY gained from CEA for a 65 year old man was 8,707 Euros and for
a 75 year old man, 26,315 Euros. Fifteen year total treatment effect in
women 65 years of age was at a projected cost of 46,421 Euros per QALY
and for a woman 75 years of age, it was 114,936 Euros per QALY.
Comment: It is estimated 34,557 Euros per QALY gained for a 65 year
old man is cost effective. At age 73 years, for men, the cost per QALY gained
with CEA was near the implicit willingness to pay for a QALY in Sweden. It
indicates that men age 73 years of age gain enough from CEA to justify
risks of CEA and high initial costs. In women, it is only those 65 years of age
or under at the time of CEA and who live 15 years who will benefit from
prophylactic CEA from a cost effective viewpoint. The data are obviously
interesting but it seems politically untenable to deny women, and not men,
prophylactic CEA for high-grade asymptomatic carotid stenosis.
Effects of Intensive Glucose Lowering in Type 2 Diabetes
The Action to Control Cardiovascular Risk in Diabetes Study Group. N
Engl J Med 2008;358:2545-59.
Conclusion: After 3.5 years intensive therapy to lower glycated hemo-
globin levels below standard recommendations in patients with Type 2
diabetes resulted in increased mortality and did not reduce major cardiovas-
cular events.
Summary: This is one of two 2 major randomized trials on glucose
lowering in patients with type 2 diabetes appearing in the June 12, 2008
issue of theNewEngland Journal ofMedicine (see also next abstract). In this
study, 10,251 patients with a mean age of 62.2 years and a median glycated
hemoglobin level of 8.1% were randomly assigned to intensive or standard
glucose control therapy. Intensive therapy targeted a glycated hemoglobin
level less than 6.0% while standard therapy targeted a level from 7.0 to 7.9%.
38% of the patients in this study were women and 35% of the patients had
had a previous cardiovascular event. Primary outcome was a composite of
non-fatal stroke, non-fatal myocardial infarction, or death from cardiovas-
cular causes. The study was stopped after 3.5 years by the safety monitoring
committee when it was found that there was a higher mortality in the
intensive therapy group.
Stable median glycated hemoglobin levels 6.4% and 7.5% were
achieved at one year in the intensive and standard therapy groups
respectively. The primary outcome occurred in 371 patients in the
standard therapy group and 352 patients in the intensive therapy group
(p0.16). There were 257 deaths in the intensive therapy group and 203
in the standard therapy group (hazard ratio 1.22; 95% CI, 1.01 to 1.46;
p0.04). Weight gains of more than 10 kilograms and hypoglycemia
requiring assistance were more frequent in the intensive therapy group
(p0.001).
Comment: This study and the Advance trial (see below) together,
randomized over 21,000 patients with type 2 diabetes to standard or
intensive diabetic control. While there was some potential hint of long term
benefit in microcardiovascular events in the Advance trial, this study identi-
fied a previously unrecognized harm of intensive glucose lowering in patients
with type 2 diabetes. Once again, when subject to the rigors of a randomized
trial, a commonly held belief appears to have been incorrect. These studies
will be intensely debated but the bottom line is there was no clear benefit
from intensive glucose control in reducing macrovascular events in patients
with type 2 diabetes.
Intensive Blood Glucose Control and Vascular Outcomes in Patients
with Type 2 Diabetes
The Advance Collaborative Group. N Engl J Med 2008;358:2560-2572.
Conclusion: Intensive glucose control in patients with type II diabetes
decreases nephropathy but has no effect on macrovascular events such as
death from cardiovascular causes, stroke or non- fatal myocardial infarcton.
Summary: The prevalence of Type 2 diabetes is increasing rapidly and
is associated with significant cardiovascular adverse effects. The authors
tested the hypothesis that, in patients with type II diabetes, intensive glucose
control as evidenced by lowering the glycated hemoglobin level to to6.5%
would result in lower rates of major microvascular and macrovascular events.
There were 11,140 patients with Type 2 diabetes who were randomly
assigned to undergo standard glucose control or intensive glucose control.
Intensive glucose control was achieved with the use of gliclazide (modified
release) and other drugs as required to reach a glycated hemoglobin6.5%.
Primary end points were composites of major microvascular events (new or
worsening nephropathy or retinopathy) or macrovascular events (death
from cardiovascular causes, non-fatal myocardial infarction, or non-fatal
stroke). End points were assessed both jointly and separately.
The mean glycated hemoglobin at a median follow-up of 5 years was
lower in the intensive control group (6.5%) than in the standard control
group (7.3%). The incidence of combined macrovascular and microvascular
events in the intensive control group was 18.1% v. 20.0% in the standard
control group (hazard ratio 0.90; 95% CI 0.82 to 0.98; p0.01). Major
microvascular events were 9.4% in intensive control and 10.9% in standard
control group (hazard ratio 0.86, 95% CE 0.77 to 0.97, p0.01). This
resulted primarily from a reduction in the incidence of nephropathy
(p0.006). There was no significant effect on retinopathy (p0.50). There
was also no significant effect of glucose control on major macrovascular
events (hazard ration with intensive control 0.94, 95% CI 0.84 to 1.06;
p0.32). There was no difference in death from cardiovascular causes
(p0.12) or death from any cause (p0.28). Significant hypoglycemia was
more common in the intensive control group (2.7% v. 1.5%, hazard ratio
1.86, 95% CI 1.42 to 2.40, p0.001).
Comment: It is disappointing that intensive glucose control did not
result in a reduction in macrocardiovascular events in patients with Type 2
diabetes. It may be, however, that longer follow-up is needed to detect such
an effect. The clear improvement in nephropathy, with longer follow up,
perhaps could be expected to have benefit over time in reducing macrovas-
cular events. This is, however, only speculation and the idea that intensive
glucose control is beneficial in patients with type II diabetes must be
seriously questioned. See also previous abstract.
ResourceUtilization and Economic Costs of Care Based on ARandom-
ized Trial of Vacuum-Assisted Closure Therapy in the Treatment of
Diabetic Foot Wounds
Apleqvist J, Armstrong DG, Lavery LA, et. al. Am J Surg 2008;195:792-
788.
Conclusion: In diabetic patients with post-amputation wounds, neg-
ative pressure wound therapy heals a greater proportion of patients with less
resource utilization than standard moist wound therapy.
Summary:There were 162 patients with diabetes and post-amputation
wounds entered into a 16 week randomized clinical trial. Seventy-seven
patients were randomized to negative pressure wound therapy NPWT) and
received dressing changes every 48 hours. Eighty-five patients received
standard moist wound (MWT) therapy according to consensus guidelines
(Wound Ostemy Continence Nursing Society. Guideline for Management
of Wounds in Patients with Lower Extremity Neuropathic Disease. WOCN
Glennville, IL; 2004: 57). Direct costs, procedures, and resource utilization
were analyzed in a post-op retrospective analysis.
In the NPWT v. MWT groups, there were no differences in inpatient
hospital stay either in terms of number of admissions or length of stay. There
were more debridement procedures required in theMWT group (120 v. 43,
p0.001). The average number of dressing changes per patient in theMWT
group was 118 (range 12-226) v. 41 (6-140) for NPWT, p0.0001. The
average direct cost per patient for 8 weeks of treatment or longer was
$27,220 for the NPWT group and $36,096 for the MWT group. The
average total cost to achieve healing was $25,954 in patients treated with
NPWT (n43) compared with $38,806 for the MWT group (n33).
Comment: It is very expensive to heal wounds. The study suggests
negative pressure therapy for open diabetic wounds is cheaper and more
effective than standard moist wound therapy. Costs in theMWT group were
driven primarily by dressing changes and antibiotic costs. It is likely that the
costs presented are conservative. Costs related to transportation, inpatient
dressing changes, prosthesis and rehabilitation were not included in the
analysis. Note the authors have affiliations with KCI, themanufacturer of the
negative pressure device used in this study.
Rivaroxaban vs Enoxaparin for Thromboprophylaxis after Hip
Arthroplasty
Eriksson BI, Borris LC, Friedman RJ. and the RECORDOne Study Group.
N Engl J Med 2008;358:2765-75.
Conclusion: In patients undergoing elective hip arthroplasty, an oral
dose of Rivaroxaban once daily is more effective than Enoxaparin for
extended thromboprophylaxis.
Summary: Extending thromboprophylaxis for five weeks following
total hip arthroplasty is more effective than short term thromboprophylaxis
in preventing venous thromboembolism (VTE). There is a Grade 1A rec-
ommendation by the American College of Chest Physicians for extended
thromboprophylaxis after hip arthroplasty.
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